Eli Lilly and Company (LLY) Stock Price, Quote & News

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 317 276 2000

Website: www.lilly.com

Address:

Lilly Corporate Center, Indianapolis, United States

Jaxson25 Jul. 3 at 3:39 PM

$LLY lets get that 600

0 · Reply

Hooooooold Jul. 3 at 1:37 PM

$NVO $LLY FOUNDAYO IS GAINING! As nvo investor im worried now! At this rate foundayo is going to overtake wegovy oral in 2086!

3 · Reply

clan Jul. 3 at 1:13 PM

$MNKD 🇺🇲 Inhalable mealtime insulin! Who knew?!? 🚫💉 #inhalemyinsulin 😲🤯 #Afrezza For the good of all diabetic Mannkind $LLY $SPY $NVO 🇺🇲💪

0 · Reply

ElliottwaveForecast Jul. 3 at 11:29 AM

$LLY continue rally against 4.29.206 low as expected in 6.11.2026 update against 1052.2 low It should remain supported in pullback in 3, 7 or 11 swings to continue rally above 1362.4 or higher. Buyers should wait for pullback to re-enter the longs. #Elliottwave #LLY

0 · Reply

michele1208 Jul. 3 at 7:29 AM

New Symphony prescription data for $NVO and $LLY • Oral Wegovy: 115,591 prescriptions in week 26 vs. 116,767 in week 25. This marks the second consecutive weekly decline, though prescriptions remain close to the all-time high of 119,227 reached in week 24. • Foundayo: 5,501 prescriptions vs. 5,167 the previous week, continuing its gradual growth. It's worth noting that Symphony does not include prescriptions filled through online pharmacies, telehealth platforms, or NovoCare. Novo recently said Oral Wegovy had surpassed 3 million U.S. prescriptions just five months after launch, while Symphony has captured about 2.0 million prescriptions over the same period.

1 · Reply

SonGoku Jul. 3 at 2:30 AM

I prolly should have been paying more attention to $LLY and not underestimating its giant MOAT..

0 · Reply

Investor203 Jul. 3 at 2:10 AM

$VNDA $LLY BO coming soon at $30

2 · Reply

idkmikes57 Jul. 3 at 12:42 AM

$LLY when is the pullback?

1 · Reply

LLYBULL Jul. 2 at 11:22 PM

$LLY Yes you will get it. After 1:10 split, then another 6 years LLY will be 600.

0 · Reply

Jaxson25 Jul. 2 at 10:35 PM

$LLY looking to get in at 600 asking for friend

0 · Reply

AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why

NVDA

2026-07-01T16:04:55.000Z - 2 days ago

Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings

Jul 1, 2026, 10:23 AM EDT - 2 days ago

Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results

2026-06-30T18:55:11.000Z - 3 days ago

Eli Lilly Stock (LLY) Retreats as China Threats Emerge

2026-06-30T09:50:28.000Z - 3 days ago

Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement

Jun 30, 2026, 5:00 AM EDT - 3 days ago

Medicare will start covering obesity drugs for the first time. Here's what patients should know

NVO

Jun 30, 2026, 1:57 AM EDT - 3 days ago

China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug

Jun 30, 2026, 12:00 AM EDT - 4 days ago

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

2026-06-29T19:44:36.000Z - 4 days ago

FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities

Jun 29, 2026, 3:03 PM EDT - 4 days ago

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

REGN

2026-06-29T19:00:12.000Z - 4 days ago

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

AMRX REGN

Jun 29, 2026, 2:50 PM EDT - 4 days ago

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

REGN

2026-06-29T14:34:54.000Z - 4 days ago

Eli Lilly Stock (LLY) Hits All-Time High as Weight-Loss Drug Sales Accelerate

NVO

Jun 28, 2026, 10:00 PM EDT - 5 days ago

GAME CHANGER: Eli Lilly launches $50 Medicare GLP-1 program

Jun 28, 2026, 8:00 AM EDT - 5 days ago

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

NVO

Jun 26, 2026, 2:39 PM EDT - 7 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE JNJ MRNA SNY XBI

2026-06-26T14:49:53.000Z - 7 days ago

Here’s Why Eli Lilly Stock (LLY) Is Up 6% Today

Jun 26, 2026, 10:45 AM EDT - 7 days ago

GLP-1s linked to smell and taste impairment in diabetes patients

NVO

Jun 26, 2026, 10:08 AM EDT - 7 days ago

Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

NVO

2026-06-26T11:20:11.000Z - 7 days ago

Eli Lilly’s Jaypirca recommended by CHMP for approval in EU

Jun 26, 2026, 7:16 AM EDT - 7 days ago

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

2026-06-25T10:55:49.000Z - 8 days ago

Eli Lilly announces more details of Medicare GLP-1 Bridge program

Jun 25, 2026, 6:45 AM EDT - 8 days ago

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

2026-06-25T10:06:09.000Z - 8 days ago

Eli Lilly price target raised to $1,232 from $1,119 at Leerink

2026-06-24T14:40:06.000Z - 9 days ago

Controversy Erupts Over Report Trump Has Early Access to Eli Lilly (LLY) Weight-Loss Drug

NYT

Jun 24, 2026, 8:45 AM EDT - 9 days ago

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Jun 24, 2026, 2:36 AM EDT - 9 days ago

China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says

Jun 23, 2026, 9:38 PM EDT - 10 days ago

Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly

Jun 23, 2026, 1:34 PM EDT - 10 days ago

How Eli Lilly Became a $1 Trillion Company

Jun 23, 2026, 12:10 PM EDT - 10 days ago

Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Jun 23, 2026, 11:51 AM EDT - 10 days ago

Fund manager names 3 non-AI stocks to own as Intel, AMD sink amid broader tech rout

GEV

Jun 22, 2026, 11:00 AM EDT - 11 days ago

Lilly declares third-quarter 2026 dividend

Jun 22, 2026, 5:30 AM EDT - 11 days ago

Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worries

NVO

Jun 17, 2026, 11:45 AM EDT - 16 days ago

Ozempic Linked To Lower Risk Of Violence In New Study

AZN NVO TWST

Jun 16, 2026, 1:06 PM EDT - 17 days ago

Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.

Jun 15, 2026, 12:30 PM EDT - 18 days ago

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

Jun 14, 2026, 3:15 AM EDT - 19 days ago

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Jun 13, 2026, 2:00 PM EDT - 20 days ago

The Next Phase Of The Obesity Drug Race

GPCR NVO

Jun 13, 2026, 11:15 AM EDT - 20 days ago

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Jun 13, 2026, 8:00 AM EDT - 20 days ago

Drugmakers race to find a place in the next wave of obesity drugs

AMGN NVO AZN

Jun 11, 2026, 2:00 PM EDT - 22 days ago

MU, GOOGL, LLY & Other Stocks Andrew Arons is Watching This Summer

GOOG GOOGL MU

Jun 11, 2026, 7:14 AM EDT - 22 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Jun 11, 2026, 6:03 AM EDT - 22 days ago

Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

NVO

Jun 10, 2026, 6:02 AM EDT - 23 days ago

Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Jun 9, 2026, 6:18 PM EDT - 24 days ago

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

Jun 9, 2026, 6:06 PM EDT - 24 days ago

As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

HUM MDT UNH

Jun 9, 2026, 3:20 PM EDT - 24 days ago

Eli Lilly and Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 2:03 PM EDT - 24 days ago

Is It Too Late To Buy The Rally In Eli Lilly Stock?

Jun 9, 2026, 9:20 AM EDT - 24 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ MRK NVO PFE

Jun 9, 2026, 4:00 AM EDT - 24 days ago

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

Jun 9, 2026, 3:20 AM EDT - 24 days ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY MRK PFE RDW UTHR XBI

Jun 8, 2026, 5:05 PM EDT - 25 days ago

Use of GLP-1 drugs early in pregnancy should not cause alarm

NVO

Jun 8, 2026, 2:30 PM EDT - 25 days ago

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Jun 8, 2026, 1:50 PM EDT - 25 days ago

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead

Jun 8, 2026, 10:30 AM EDT - 25 days ago

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

NVO

Jun 8, 2026, 10:30 AM EDT - 25 days ago

Monday's Morning Movers: MU & SNDK PT Hikes, LLY Foundayo Delivers

SNDK MU

Jun 8, 2026, 7:06 AM EDT - 25 days ago

Lilly shares jump as analysts see retatrutide data extending obesity market edge

Jun 8, 2026, 6:16 AM EDT - 25 days ago

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Jun 8, 2026, 5:44 AM EDT - 25 days ago

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

Jun 8, 2026, 5:35 AM EDT - 25 days ago

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

Jun 7, 2026, 11:00 AM EDT - 26 days ago

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Jun 6, 2026, 7:00 PM EDT - 27 days ago

Eli Lilly and Company Transcript: American Diabetes Association (ADA) 86th Scientific Sessions

Jun 6, 2026, 7:00 PM EDT - 27 days ago

Eli Lilly and Company Slides: American Diabetes Association (ADA) 86th Scientific Sessions

Jun 6, 2026, 2:53 PM EDT - 27 days ago

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Jun 6, 2026, 2:34 PM EDT - 27 days ago

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Jaxson25 Jul. 3 at 3:39 PM

$LLY lets get that 600

0 · Reply

Hooooooold Jul. 3 at 1:37 PM

$NVO $LLY FOUNDAYO IS GAINING! As nvo investor im worried now! At this rate foundayo is going to overtake wegovy oral in 2086!

3 · Reply

clan Jul. 3 at 1:13 PM

$MNKD 🇺🇲 Inhalable mealtime insulin! Who knew?!? 🚫💉 #inhalemyinsulin 😲🤯 #Afrezza For the good of all diabetic Mannkind $LLY $SPY $NVO 🇺🇲💪

0 · Reply

ElliottwaveForecast Jul. 3 at 11:29 AM

0 · Reply

michele1208 Jul. 3 at 7:29 AM

1 · Reply

SonGoku Jul. 3 at 2:30 AM

I prolly should have been paying more attention to $LLY and not underestimating its giant MOAT..

0 · Reply

Investor203 Jul. 3 at 2:10 AM

$VNDA $LLY BO coming soon at $30

2 · Reply

idkmikes57 Jul. 3 at 12:42 AM

$LLY when is the pullback?

1 · Reply

LLYBULL Jul. 2 at 11:22 PM

$LLY Yes you will get it. After 1:10 split, then another 6 years LLY will be 600.

0 · Reply

Jaxson25 Jul. 2 at 10:35 PM

$LLY looking to get in at 600 asking for friend

0 · Reply

StockRadarr Jul. 2 at 8:07 PM

$NVO sema usage at 40% vs $LLY TZP at 60% says a lot. Beyond self-pay, it gets even tougher for sema. If you split it out, 5 mg TZP looks stronger than full-dose sema, with fewer side effects. That’s where you start questioning why a primary doc or specialist would choose the weaker option.

1 · Reply

joe77w Jul. 2 at 7:32 PM

$SGMO $LLY Lilly and Astellas May be the winners but with likely well higher offers. It Is a matter of time. 50 cents or 200 mln USD in net equity Is not impossible. If Fabry disease approval almost sure how Is It possible big Pharmaa not bidding against Astellas offering 2x/3x ? It Is an auction, Who pays more take It all clean and without milestone and royalties attached if I understand well. Stalking horse bidders offers too cheap imo with all that potential. 🤞🤞🤞🤞

0 · Reply

SwingTraderPro1 Jul. 2 at 7:30 PM

They say the “Trump journal” trade log is insane: Reported ~$1B+ crypto gains in 2025 Accumulated $MU during the March 2026 crash dip ~21,000 trades executed in 2025 (high-frequency style positioning) Often bullish after positioning first, then public commentary follows Past mentions still echo through the tape: $PLTR called out around $125 zone $LLY referenced near $1100 levels Whether you believe the narrative or not, the takeaway traders focus on is simple: positioning first, narrative second, attention last. Tape always follows flow, not headlines.

0 · Reply

BreakoutLife Jul. 2 at 7:21 PM

Market chatter has been circulating a “Trump journal” style narrative highlighting various claims around trading activity and market commentary in 2025–2026, including mentions of crypto gains, high trade frequency, and timing around major stocks. Within that narrative, $MU is referenced during a 2026 drawdown period, $PLTR around the $125 area, and $LLY near the $1100 level. While these stories tend to generate engagement, the actual market relevance should always be separated from rumor-driven interpretation and focused on verified price action and fundamentals. In reality, markets don’t move on anecdotes - they move on liquidity, positioning, and earnings power.

0 · Reply

CosmicMiner Jul. 2 at 7:16 PM

Market updates on high-profile names: $MU is stabilizing with base support after the March dip. $PLTR extended its bullish momentum above the key $125 technical level. $LLY scaled past $1100, testing macro resistance near all-time highs.

0 · Reply

NDXbull Jul. 2 at 6:25 PM

$LLY sold $SMH to buy Eli Lily.

0 · Reply

biotech Jul. 2 at 6:20 PM

$SGMOQ / $SGMO — The zombie biotech lotto ticket Wall Street forgot to price properly But this one is weird. This is not the classic “company drowned in debt, creditors own everything, equity goes to zero” bankruptcy $LLY and #Astellas already acting as stalking-horse

2 · Reply

Buffetty Jul. 2 at 6:14 PM

$LLY $MU this rotation worked out well

0 · Reply

FutureBulls Jul. 2 at 6:01 PM

$NKTR is looking stale here. 10 weeks since the $92 offering, and ph3 still hasn’t kicked off. Last meaningful $LLY litigation update was April 16th, before that it was basically monthly. Mgmt last showed up June 4 at the AGM, and the last relevant PR was end of May. Quiet tape, fading catalysts, cold momentum.

1 · Reply

Danzzzzzzzz Jul. 2 at 3:51 PM

$BMY $LLY $NVS $PNT $RYZB

0 · Reply

Ryuk Jul. 2 at 3:51 PM

$LLY +400%

0 · Reply

BreakoutLife Jul. 2 at 3:50 PM

$LLY is primed and ready to ignite its next right-side macro leg up on the tape. Following a very clean and healthy structural consolidation, the chart setup is demonstrating high-probability trend continuation. The path for an explosive upside expansion has officially cleared, with the immediate technical target locked at $1280, followed by the major macro extension toward the $1400 milestone. Strong momentum runner to watch.

0 · Reply

Market Cap	1,143.19B
Revenue (ttm)	65.18B
Net Income (ttm)	20.64B
EPS (ttm)	N/A
PE Ratio	40.51
Forward PE	33.35
Profit Margin	31.67%
Debt to Equity Ratio	1.26

Volume	3,297,400
Avg Vol	3,411,884
Day's Range	N/A - N/A
Shares Out	941.74M
Stochastic %K	85%
Beta	0.51
Analysts	Strong Sell
Price Target	$1,248.82